RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • Aqueous Electrochemistry of Poly(vinylanthraquinone) for Anode-Active Materials in High-Density and Rechargeable Polymer/Air Batteries

        Choi, Wonsung,Harada, Daisuke,Oyaizu, Kenichi,Nishide, Hiroyuki American Chemical Society 2011 JOURNAL OF THE AMERICAN CHEMICAL SOCIETY - Vol.133 No.49

        <P>A layer of poly(2-vinylanthraquinone) on current collectors underwent reversible electrode reaction at −0.82 V vs Ag/AgCl in an aqueous electrolyte. A repeatable charging/discharging cycles with a redox capacity comparable to the formula weight-based theoretical density at the negative potential suggested that all of the anthraquinone pendants in the layer was redox-active, that electroneutralization by an electrolyte cation was accomplished throughout the polymer layer, and that the layer stayed on the current collector without exfoliation or dissolution into the electrolyte during the electrolysis. The charging/discharging behavior of the polymer layer in the aqueous electrolyte revealed the capability of undergoing electrochemistry even in the nonsolvent of the pendant group, which offered insight into the nature of the anthraquinone pendants populated on the aliphatic chain. Charging/discharging capability of air batteries was accomplished by using the polymer layer as an organic anode-active material. A test cell fabricated using the conventional MnO<SUB>2</SUB>/C cathode catalyst exhibited a discharging voltage at 0.63 V corresponding to their potential gap and a charging/discharging cycle of more than 500 cycles without loss of the capacity.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jacsat/2011/jacsat.2011.133.issue-49/ja206961t/production/images/medium/ja-2011-06961t_0004.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/ja206961t'>ACS Electronic Supporting Info</A></P>

      • KCI등재

        Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study

        Hideto Ueki,Takuto Hara,Yasuyoshi Okamura,Yukari Bando,Tomoaki Terakawa,Junya Furukawa,Kenichi Harada,Yuzo Nakano,Masato Fujisawa 대한비뇨의학회 2022 Investigative and Clinical Urology Vol.63 No.4

        Purpose: Two methods are used to identify sarcopenia by calculating skeletal muscle area on computed tomography: the skeletal muscle index (SMI) and the psoas muscle index (PMI). Programmed death (PD)-1 inhibitors are helpful in treating metastatic renal cell carcinoma (mRCC). However, there remains insufficient information regarding a clear and easy-to-use biomarker for predicting the response to PD-1 inhibitors in patients with mRCC. Therefore, we investigated the influence of sarcopenia on clinical outcomes in patients with mRCC undergoing treatment with nivolumab. Materials and Methods: This study evaluated 96 patients with RCC who received nivolumab. The SMI and PMI were calculated for each patient and normalized for stature by use of the following formulas: SMI (cm2/m2)=([skeletal muscle cross-sectional area at the level of L3]/[height]2) and PMI (cm2/m2) = ([left-right sum of the psoas muscle areas at the level of L3]/[height]2). The relationship of the clinical variables with progression-free survival and overall survival (OS) was examined using a Cox proportional hazards model. Results: According to the SMI-based definition of sarcopenia, 74.0% of patients had sarcopenia. However, according to the PMI-based definition of sarcopenia, only 34.3% of patients were diagnosed with sarcopenia. Multivariate analysis identified sarcopenia based on PMI (hazard ratio [HR], 3.85; 95% confidence interval [CI], 2.04–7.26; p<0.001) and International Metastatic RCC Database Consortium poor risk status (HR, 1.90; 95% CI, 1.03–3.50; p=0.041) as significant and independent prognostic factors of OS. Conclusions: PMI-based sarcopenia is a significant prognostic factor for OS in patients with RCC who receive nivolumab therapy.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼